期刊文献+

三种抗惊厥药物预防动物热性惊厥的比较研究 被引量:2

Comparison of Preventive Effects of Topiramate, Valproate and Phenobarbital on Febrile Conrulsion in Rats
下载PDF
导出
摘要 目的动态观察大鼠药物干预后反复热性惊厥(FC)发生情况,探讨抗惊厥药物预防动物FC的疗效及其差异。方法 SD大鼠78只,用热水浴法制备反复FC大鼠模型。分为妥泰(TPM)组、苯巴比妥(PB)组、丙戊酸钠(VPA)组、生理盐水对照组。实施药物干预的同时,每两天使大鼠FC一次,记录大鼠对惊厥敏感程度的改变情况。结果大鼠用药后,药物处理组较对照组发生惊厥的潜伏期显著延长(F=4.2,P<0.01),惊厥持续时间显著缩短(F=28.2,P<0.01),惊厥严重程度显著减轻(F= 21.4,P<0.01)。其中,TPM组惊厥持续的时间较VPA组、PB组显著缩短(q=3.8、3.0,P<0.05),TPM组和PB组的惊厥发生的程度较VPA组显著减轻(P<0.05)。结论妥泰、丙戊酸钠和苯巴比妥都具有预防动物FC的作用,其中以妥泰的预防效果最好。 Objective To explore the preventive effects of topiramate ( TPM ) , phenobarbital ( PB ) and valproate (VPA) on febrile convulsion. Methods Seventy - eight Sprague - Dawley ( SD ) rats were randomly divided into control , TPM - treated, VPA - treated and PB - treated groups. Febrile convulsions were induced every other day by hyperthermal bath at 45℃. The different drugs were orally administered to the rats of different groups twice a days for 5days,and then once again immediately before each hyperthermal bath. The manifestations of febrile convulsions were observed in all the groups. Results The incubation period of the febrile convulsion was signficantly longer, the duration of the convusion was significantly shorter and the convusion was significantly alleviated in all the experimental groups compared with the control group ( P 〈 0.05 ). The duration of convulsion were significantly shorter in TPM - treated group than that in VPA - treated group and PB - treated ( P 〈 0.05 }. The convulsion were significantly alleviated in TPM - treated and PB - treated groups compared to VPA - treated group ( P 〈 0.05 ). Conclusions Continuous administration of three antiepilepsy drugs is of preventive effect on the febrile convulsion. Among them ,TPM was likely the best for preventing the febrle convulsion.
作者 黄志 李娟
出处 《华南国防医学杂志》 CAS 2006年第2期12-14,共3页 Military Medical Journal of South China
基金 重庆市科委自然科学基金资助项目 (NO:200454101)
关键词 妥泰 热性惊厥 预防 Topiramate Febrile convulsion Prophylaxis
  • 相关文献

参考文献7

二级参考文献17

  • 1匡培根.偏头痛的研究进展与展望[J].中国实用内科杂志,1993,13(12):707-709. 被引量:43
  • 2徐新献 熊安岭 刘本泉 徐新献 徐立新 陈平 主编.新生儿缺氧缺血性脑病[A].徐新献,徐立新,陈平,主编.儿科危重病症现代治疗:第1版[C].成都:四川科学技术出版社,1997.18-19.
  • 3Stephen DS, Walter N, Jennifer S, et al. Topiramate in migraine prevention: results of a large controlled trial[J].Arch Neurol, 2004,61 : 490.
  • 4Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, ransformed migraine, and cluster headache with topiramate[J]. Headache, 2002,42 (8) : 796.
  • 5Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study[J]. Headache, 2001,41 (10) : 968.
  • 6Maytal J,Young M,Shechter A, et al. Pediatric migraine and the International Headache Society (IHS) criteria[J]. Neurology, 1997,48 : 602.
  • 7Krymchantowski A ,Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting[J]. Med Gen Med,2004,6(3) : 48.
  • 8Paseual J,Sanehez del Rio M, Mateos V, et al. Topiramate for patients with refractory migraine: an observational,multicenter study in Spain[J]. Neurologia, 2003,18 (7) :364.
  • 9Cutrer FM. Antiepileptie drugs: how they work in headache[J]. Headache,2001, 41(Suppl 1) :S3.
  • 10Edwards KR, Potter DL, Wu SC, et al. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials[J]. CNS Spectr,2003,8(6) :428.

共引文献25

同被引文献13

  • 1Jiang W, Duong TM, Lanerolle NC. The neuropathology of hyperthermic seizures in the rats[J]. Epilepsia, 1999, 40(1 ) :5-19.
  • 2Patsalos PN. Pharmacokinetic profile of levetiracetam : toward ideal characteristics [ J]. Pharmacol Ther, 2000, 85 (2):77-85.
  • 3Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain [J]. Br J Pharmacol, 2001 , 133(6) :867- 874.
  • 4Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levitiracetam in patients with moderate to severe liver cirrhosis ( Child-Pugh classes A. B and C ) : characterization by dynamic liver function tests [J]. Clin Pharmacol Ther, 2005, 77 ( 6 ) :529-541.
  • 5Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levitiracetam does not modulate neuronal voltagegated Na^+ and T-type Ca^2+ currents [J]. Seizure, 2001, 10 (4) :279-286.
  • 6Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? [J]. Epilepsia, 2001, 42 (Suppl 4) : 13- 18.
  • 7Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam [ J ]. Proc Natl Acad Sci USA, 2004, 101 (26) :9861-9866.
  • 8Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca^2 + current in pyramidal near ones of rat hippocampal slices [ J]. Neurosci Leet, 2001,306 (1- 2) :5-8.
  • 9Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture [ J ]. Neurosci Lett, 2008, 436(3) :289-293.
  • 10K. Lee,J. C. Melchior. Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood[J] 1981,European Journal of Pediatrics(2):151~153

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部